article
Mass Spectrometry In-Depth Focus 2017
In this Mass Spectrometry In-Depth Focus: Mass spectrometry in the development of protein biologics; and GC-MS applications in pharmaceuticals analysis...
List view / Grid view
Biologics
webinar
Rethinking Collaboration in Biologics Discovery
4 April 2017 | By Dassault Systèmes BIOVIA
In this webinar, Anne Goupil-Lamy, Ph.D. from BIOVIA demonstrated, using a case study, the value of bringing real time data together during the project: genomics data, predictive models, and experimental assay data...
article
The British Pharmacopoeia – in 2017 and beyond
The British Pharmacopoeia (BP) is a collection of authoritative and publicly available quality standards for medicines, supported by guidance and additional value-adding information. First published in 1864, the BP has an illustrious history that has been built on quality and continually responds to the needs of stakeholders and users.
news
Celltrion to develop assay for evidence-based decision-making in anti-TNF treatment
5 July 2016 | By Victoria White, Digital Content Producer
Celltrion is to develop laboratory tests that will enable physicians to identify when patients on an anti-TNF drug require a change of dose...
news
Pfizer breaks ground on new biologics manufacturing facility
17 June 2016 | By Victoria White, Digital Content Producer
Pfizer will invest more than $200 million in the development of the state-of-the-art facility that will enable the production of high-quality, complex biologics...
news
Sanofi makes huge investment in the future of biologics
19 April 2016 | By Mandy Parrett, Editorial Assistant
Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.
whitepaper
Whitepaper: Bioanalytical support in the development of biologics
In this publication Imperacer® case studies demonstrate the advantage of broad assay range combined with excellent sensitivity for several Biologics on their way from R&D to clinics...
webinar
Integrated, predictive and collaborative workflows in biologics discovery
23 March 2016 | By Dassault Systèmes BIOVIA & GlaxoSmithKline
As well as delving into secure data sharing, the speakers from BIOVIA and GSK will discuss implementing the BIOVIA Biological Registration solution. The speakers will highlight the importance of effective IP protection and improved decision-making through an integrated and collaborative platform...
news
Tecan simplifies large molecule bioanalysis
Tecan has launched a fully automated affinity purification solution for the extraction of large biomolecules, such as proteins, antibodies and antibody-drug conjugates. This set-up takes advantage of the new Thermo Scientific™ MSIA™ Streptavidin EVO microcolumns, which have been specifically designed for use on Tecan’s proven Freedom EVO® platform. In combination…
article
Meeting biopharmaceutical analytical requirements for subvisible particle sizing and counting
22 October 2015 | By John Carpenter, University of Colorado / Amber Haynes, Fradkin KBI Biopharma / Christina Vessely, Biologics Consulting Group Inc.
Quantifying and sizing subvisible particles in biopharmaceutical products are crucial aspects of formulation development, stability studies, process development, product release and extended characterisation of the final drug product.
news
Record attendance for Cambridge Healthtech Institute’s Seventh Annual PEGS Europe Summit
16 October 2015 | By CHI
Largest European Event for Biologics Returns to Lisbon from 2-6 November...
news
What is a biosimilar medicine? NHS England explains all in new publication
25 September 2015 | By Victoria White
The British Generic Manufacturers Association, the Association of the British Pharmaceutical Industry (ABPI), and the UK BioIndustry Association (BIA) have joined forces to welcome NHS England’s new publication “What is a biosimilar medicine?”.
news
UCB secures multi-million pound funding boost from UK Government
UCB has announced that its joint bid with five other UK-based organisations has been selected as a recipient of the Government’s 2014 Advanced Manufacturing Supply Chain Initiative (AMSCI), which will result in a £6.2 million grant to support the development of novel biologic treatments.
article
Issue #1 2015 – Digital edition
In Issue #1 2015: Regulatory Insight, Biologics, NIR in-depth focus, Raman in-depth focus, PAT, Drug Delivery, Microbiology Series and much more...
article
TandAbs: potent and well-manufacturable bi-specific antibodies for immunooncology
10 March 2015 | By Michael Weichel, Kristina Ellwanger, Ivica Fucek, Stefan H.J. Knackmuss, Erich Rajkovic, Uwe Reusch, Claudia Wall, and Eugene A. Zhukovsky, Affimed Therapeutics AG
The bi-specific antibody format is becoming the preferred antibody modality for current development projects in the pharmaceutical industry. This is due to an unsurpassed increase in functional activity relative to traditional mono-specific monoclonal antibodies, and a breakthrough in manufacturability enabled by novel designs. One such bi-specific format, the TandAb, produces…
